Abstract: Primary human fetal brain neural stem cells (hNSCs) are a unique non-genetically modified model system to study molecular mechanisms underlying human neural development, to model human diseases, and to screen drugs or validate new treatments. They may also be used for cell transplantation to treat various neurological diseases. This protocol details our methods that can be used to expand hNSCs in culture as well as how to differentiate them into various neuronal lineages and astrocytes.
Introduction
Understanding the regulation of neural stem cell proliferation, differentiation, and survival is critical for developing treatments for a variety of developmental and neurodegenerative disorders. Many of the mechanisms governing these functions remain poorly understood. 1, 2 Researchers have utilized animal models to study neurological development and degeneration in vivo. 3 While animal models have yielded valuable information, they are both time consuming and genetically different from humans. Researchers have also employed genetic manipulations to induce differentiated human cells to become stem cells. 4 These cells are commonly referred to as induced pluripotent stem cells. While these cells are human and have the advantage of being isolated directly from patients, the genetic manipulations to induce pluripotency provide an additional variable into an already complex system. In order to study some neurological disorders, use of non-genetically modified primary human neural stem cells is optimal.
Human fetal brain neural stem cells (hNSCs) provide a unique culturing system to understand the mechanisms governing hNSCs behavior without any genetic modifications. These cells can be expanded in culture and maintained as stem cells, or differentiated into various types of neurons and astrocytes. Culture of these cells has been used in multiple studies ranging from infectious disease to amyotrophic lateral sclerosis. [5] [6] [7] This system is particularly powerful if multiple donors can be found as individual differences can be evaluated. However, the technical challenges associated with effect and reproducible hNSC culture still present a barrier in the field. Even though many people currently use similar growth factors, media, and isolation techniques, there is considerable variability in hNSC behavior in culture over time among laboratories. This cell culture is highly sensitive to chemical and mechanical manipulations, which can greatly impact the quality of the culture and subsequent results. In order to enhance reproducibility of hNSC study findings, we have developed specific protocols on how to handle and treat hNSCs to reduce cell death, premature differentiation, and genetic mutation.
The following protocol details expansion and differentiation of hNSC populations, while emphasizing the technical subtleties that will help reduce variation in results. We believe this protocol is most helpful to investigators who wish to establish hNSC cultures in their respective labs to address a variety of projects concerning the impact of exogenous stimuli on neural stem cell survival and differentiation. The hNSCs used in this protocol were originally derived from discarded human fetal cortexes in the first trimester, and their isolation and initial expansion are described in a previous publication. 8 Following this initial expansion, vials of cells were frozen and stored in liquid nitrogen; these are the vials of cells used in this protocol. All protocol procedures adhere to the University of Texas Medical Branch ethics guidelines concerning the use of human tissue samples, and the cell lines were approved by the Institutional Biosafety Committee.
Protocol
Media preparation and initial seeding and then discard supernatant. 11. Resuspend the cell pellet in additional 10 mL of DMEM/ F12 stock medium and centrifuge again at 200×g for 5 minutes. 12. During the 5-minute spin, retrieve the pre-coated flask from the incubator and prepare the growth media by adding the growth factors listed in Table 1 to the final pre-heated 10 mL aliquot of DMEM/F12 stock medium. Note: Mixture contains 100 mg/mL transferrin, 100 mM putrescine, 20 nM progesterone, 30 nM sodium selenite. OPTIONAL: 10% N2 supplement (Gibco). 13. Remove the conditioned media from flask and add the 5 mL of pre-heated conditioned media to the flask. 14. Retrieve the cells from the centrifuge and remove the supernatant, leaving the cell pellet intact. 15. Resuspend cell pellet in 10 mL of freshly prepared growth media in Step 12 and add to the T-75 flask containing pre-warmed conditioned media. 16 and all medium components. 3. Prepare the DMEM/F12 stock medium as already described for media changes. You will need 10 mL of new media per flask. 4. Prepare appropriate amount of dPBS and glucose for the trypsin solution as described in Table 2 and place in water bath to warm. Do not add trypsin or DNase at this time. a. One milliliter of solution for approximately 10 million cells or 3 mL for approximately 30 million cells. 5. Obtain a clean small weigh boat, a hemocytometer, and a glass cover slip (usually sterilized and stored in 70% ethanol). Clean with 70% ethanol and allow to air dry in hood. 6. Obtain flask that will be passaged from the incubator and bring into the tissue culture hood. 7. Tilt flask gently and remove 5 mL of conditioned media from the top as described in the changing media procedure as already described, and put into clean 15 mL tube labeled "CM" and the date. 8. Remove another 5 mL of medium and place in the CM tube; be careful not to aspirate any cells. 9. Remove the remaining 5 mL of media along with the cells and place in a clean 15 mL tube labeled as "Cells". 10. Use the 3 mL of conditioned media in the "CM" tube to rinse the bottom of the flask in 3 mL portions. Then, place the 10 mL into the "Cells" tube. a. This rinsing process helps ensure all cells will be collected for passaging. 11. Centrifuge "Cells" at 100×g for 5 minutes. 12. While cells are spinning, obtain the dPBS/glucose solution from 37°C water bath and add the appropriate amount of trypsin and DNase according to Table 2 . 13. After the "Cells" centrifugation is complete, remove all supernatant and transfer it into the "CM" tube. 14. Resuspend the cell pellet in the appropriate volume of trypsin solution and triturate the solution approximately 5-10 times, and then incubate at 37°C for 5 minutes. Note: The amount of trypsin is depended upon the number of cells per T-75 flask. Generally, 1 mL of trypsin is sufficient for 7-10 million of cells, and thus 3 mL per T-75. 15. During this incubation, prepare the same volume of trypsin inhibitor that was used for the trypsin solution. Prepare the trypsin inhibitor by placing 1-3 mL of conditioned media (same volume as the trypsin solution) in a "Trypsin Inhibitor" labeled tube. Refer to Table 3 for the appropriate amount of trypsin inhibitor for each volume. a. Place trypsin inhibitor at 37°C until needed. 16. After 5 minutes, retrieve cells being trypsinized and triturate 5-10 times, and then incubate at 37°C for an iii. Average the two sides together. iv. Multiply this number by 10,000, which will give you the total number of cells per mL. ELL priming (for neuronal differentiation)
1. A total of 2-3 days before priming, passage the cells as already described. 2. The day before priming, coat plate or flask with PDL and laminin as already described. 3. On priming day, obtain the correct number of cells from the flask by calculating the number of cells per mL in the flask. Centrifuge the cell suspension to obtain a cell pellet at 216×g for 3 minutes. 4. Prepare the priming medium during centrifuge time according to Table 5 . 5. Aspirate laminin from the wells of the plate or flask. 6. Resuspend the cell pellet with the proper volume of priming media and load into plate or flask. 7. Incubate the plate at 37°C with 8.5% CO 2 for 4 days.
FHL priming (for motor neuron differentiation)
1. Follow the same protocol as already described; however, make the priming media according to Table 6 .
Neuronal differentiation after priming 
Astrocyte differentiation
Note: The following protocol is derived from Life Technologies, and yields approximately 90% astrocytes in a total population.
1. Two to three days prior to differentiation, passage cells. 2. Thaw a bottle of Geltrex ® matrix (Thermo Fisher Scientific, Cat. No. 12760) at 4°C overnight, and then on the next day dilute it in the ratio of 1:2 with ice cold DMEM/F12 media to make a 100× stock. a. Keep the bottles on ice and quickly aliquot 0.5 mL of solution into 50 mL conical tubes, which are also kept on ice. Store these tubes at -20°C. 3. Thaw one of the aliquots at 4°C, and add 49.5 mL of ice cold DMEM/F12 (1:100 dilution) and then mix gently. 4. Cover the surface of each plate with the solution (1.5 mL for a 35 mm dish, 3 mL for a 60 mm dish, 5 mL for a T-25 culture flask), and seal with parafilm to prevent evaporation., a. Incubate for 1 hour at room temperature in the tissue culture hood. 
GABA neuron differentiation
Note: The following protocol yields a population of approximately 40% GABA neurons. a blocking solution of 5% normal serum (NS), 0.3% bovine serum albumin (BSA), and 0.25% Triton X-100 in TBS. For example, to make 1 mL of blocking solution, you would need: a. 850 µL of 0.25% Triton X-100 b. 50 µL of 100% NS c. 100 µL of 3% BSA Note: The key of preparing the blocking solution is the selection of a right NS, which is determined by the host of the secondary antibody. For example, if the secondary antibody is derived from goat, normal goat serum should be selected.
5. During the blocking step, prepare the primary antibody solution.
a. For validating hNSCs, proteins such as Nestin and Sox2 can be targeted using the appropriate antibody against them. b. For differentiation, markers such as MAP2 can be used to identify neuronal populations, while glial fibrillary acidic protein (GFAP) can be used to identify astrocytes. c. Various markers for specific neuronal cell types can also be used for further characterization of the cells. 6. To prepare the primary antibody solution, keep all reagents on ice. 7. Centrifuge the primary antibody at 12,000×g for 2 minutes at 4°C. 8. Place the appropriate amount of antibody in an ice cold 0.25% Triton X-100 solution to reach the desired concentration. 9. Add appropriate amount of antibody solution to each well, for example, approximately 300 µL for each well in a 24-well plate. 10. Incubate the cells with primary antibody for 2 hours at room temperature or overnight at 4°C. 11. After the incubation, wash cells with TBS three times at room temperature for 10 minutes each. 12. Centrifuge the secondary antibody at 12,000×g for 2 minutes at 4°C. 13. IMPORTANT: From now onward, all steps must be conducted in a darkened room, and antibody and cells should be protected from light as much as possible. 14. Dilute the appropriate fluorescent secondary antibody (such as Alexa Fluor) to the recommended concentration (Alexa Fluor is typically 1:500) in 0.25% Triton X-100 solution. 15. After the final TBS wash, add 300 µL of the secondary antibody solution to each well and incubate in the dark for at least 1 hour at room temperature. 16. After the incubation, wash the cells three times with TBS for 10 minutes each. 17. Dilute DAPI nuclear stain to recommended concentration in TBS (typically 1:5,000). 18. After the final wash, add 300 µL of DAPI solution to each well and incubate for 5 minutes at room temperature. 19. Rinse with TBS once before using a fluorescent mounting media such as Fluoromount G to mount the coverslips by placing a thin line of media on a glass slide. 20. Carefully use tweezers to remove coverslips from the 24-well plate wells and place the cell surface down on the mounting media on the slide. a. Make sure to label slides with all relevant information needed to identify the cells on that slide. 
Representative results
Cultured hNSCs in their proliferative stage will grow as nonadherent neurospheres (Figure 1 ). Immediately following hNSC passage, there will be many individual cells, which, in the next few days, will aggregate and begin to form spheres. At 9-10 days following a passage, healthy spheres should be approximately 0.5-1 mm in diameter. Spheres that grow larger than 2 mm will develop a dark center, and the growth factors in the media will not be able to reach the cells in the center of the sphere, resulting in unwanted differentiation. Healthy spheres will appear translucent and display pseudocilia around the edges of the sphere (Figure 1 ). Plating neurospheres on an adherent surface for differentiation purposes will result in growth of an adherent culture (Figure 2 ). Priming and differentiating the cells require the cells to adhere to a coverslip at the bottom of a cell culture plate, such as a 24-well plate. The cells start to migrate out after priming and differentiating. The migration pattern is apparently different between ELL priming ( Figure 2A ) and FHL priming ( Figure 2B ).
To identify and confirm the phenotype of neurons or astrocytes generated from the differentiation experiments, various fluorescent immunohistochemistry can be used. GABAergic or glutamatergic neurons can be stained using GABA or glutamate-specific antibodies in ELL-primed and differentiated cells, respectively ( Figure 2C-D) . Following FHL priming, more motor neurons are expected and therefore choline acetyltransferase can be used to identify this population ( Figure 2E ). These results provide an example representation of immunocytochemical findings. Full immunocytochemical and electrophysiological characterization of these cells has been previously published, and can be referred to for additional neuronal markers and electrophysiological profile. 9 Although the priming step is used to achieve a higher percentage of neurons following differentiation, there will still be astrocytes in the culture. GFAP can be used to label astrocytes in order to quantify which percentage of differentiated cells became astrocytes or neurons. Additionally, GFAP can be used to identify astrocytes following enriched astrocyte differentiation ( Figure 2F ).
Discussion
In this protocol, we have described key steps and considerations for reducing variability in culturing methods in order to obtain a productive hNSC culture. The ability to culture and manipulate hNSCs provides a critical tool that can be used for a variety of purposes from modeling human disease to high throughput drug screening. [6] [7] [10] [11] [12] One of the challenges with hNSC culture is maintaining the "stemness" of the culture. Svendsen et al developed a method in 1998 to maintain primary human fetal neural stem cells in culture by chopping neurospheres into pieces. 8 Svendsen's protocol has been used and adjusted in a number of laboratories. In our protocol, half the amount of FGF and heparin is used. In addition, we developed a way to completely dissociate neurospheres into single cells, which allows us to propagate hNSCs for about 100 passages and with minimal chromosomal alteration. 7, 9 Another crucial part of culturing hNSCs is the passaging step. This step is the source of many errors. It is important to note if there are many dead or non-dissociated cells following the trypsinization process. If there are many dead cells, reduce the number of times of pipetting up and down during dissociation, as too much mechanical stress can result in cell death. Alternatively, if large amounts of clustered cells remain, the dissociation will have to be more vigorous, as these clusters will quickly become large spheres that will promote cell differentiation in culture.
Using the aforementioned protocol, hNSCs were propagated and then transplanted into the brains of mice following traumatic brain injury, which resulted in decreased accumulation of amyloid precursor protein. 13 This transplantation reduced microglial activation and diminished inflammatory mediators. 13 These results pose further interesting applications of hNSC culture for transplantation and mediation of glial responses. The role of glial progenitors and transplantation is critically important due to their proven role in rescuing myelination phenotype in mice. [14] [15] [16] NSCs play pivotal roles in everything from infection to psychiatric disorders. Multiple studies from our lab have utilized these hNSC culture and differentiation techniques to improve efficacy of stem cell transplantation in the context of traumatic brain and spinal cord injury. 9, 17, 18 We have also used hNSC culture to investigate Zika virus-associated neuropathology. 7 Since these hNSCs are not genetically modified and isolated from individual donors, it is possible to investigate factors that impact how individuals will respond to various stimuli such as Zika virus. 7 In vitro studies using hNSCs not only provide unique insight into basic stem cell behavior, but also provide an excellent platform to conduct The Journal of Neurorestoratology is an international, peer-reviewed, open access online journal publishing original research and review articles on the subject of Neurorestoratology. To provide complete coverage of this revolutionary field the Journal of Neurorestoratology will report on relevant experimental research, technological advances, and clinical achievements. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials. php to read real quotes from published authors.
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Culturing primary human neural stem cells pre-clinical research. Recently, this hNSC culture system was used to screen FDA-approved drugs to prevent Zika virus infection of NSCs. 6, 7 
